Experienced in Myeloproliferative Neoplasms (MPN)

Ilya Kirgner

Tel Aviv, TA, IL 
Experienced in Myeloproliferative Neoplasms (MPN)
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Ilya Kirgner practices in Tel Aviv, Israel. Mr. Kirgner is rated as an Experienced expert by MediFind in the treatment of Myeloproliferative Neoplasms (MPN). His top areas of expertise are Adult Immune Thrombocytopenia, Thrombocytopenia, Immune Thrombocytopenic Purpura (ITP), Purpura, and Splenectomy.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Myeloproliferative Neoplasms (MPN).

Gender
Male

Locations

Tel Aviv, TA, Israel
Other Locations
Jaffa, TA, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
View 1 Less Clinical Trial

26 Total Publications

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study.
Journal: Blood
Published: October 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kirgner's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile